Advertisement
help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
The Oncologist, Vol. 11, No. 4, 397-408, April 2006; doi:10.1634/theoncologist.11-4-397
© 2006 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by van Horssen, R.
Right arrow Articles by Eggermont, A. M. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van Horssen, R.
Right arrow Articles by Eggermont, A. M. M.

Sarcomas

TNF-{alpha} in Cancer Treatment: Molecular Insights, Antitumor Effects, and Clinical Utility

Remco van Horssen, Timo L. M. ten Hagen, Alexander M. M. Eggermont

Department of Surgical Oncology, Erasmus MC–Daniel den Hoed Cancer Center, Rotterdam, The Netherlands

Key Words. Cancer • TNF-{alpha} • TNFR-1 • Tumor vasculature • Isolated limb perfusion

Correspondence: Alexander M. M. Eggermont, M.D., Ph.D., Erasmus MC–Daniel den Hoed Cancer Center, Department of Surgical Oncology, 301 Groene Hilledijk, 3075 EA Rotterdam, The Netherlands. Telephone: 31-0-10-439-1911; Fax: 31-0-10-439-1011; e-mail: a.m.m.eggermont{at}erasmusmc.nl

Tumor necrosis factor alpha (TNF-{alpha}), isolated 30 years ago, is a multifunctional cytokine playing a key role in apoptosis and cell survival as well as in inflammation and immunity. Although named for its antitumor properties, TNF has been implicated in a wide spectrum of other diseases. The current use of TNF in cancer is in the regional treatment of locally advanced soft tissue sarcomas and metastatic melanomas and other irresectable tumors of any histology to avoid amputation of the limb. It has been demonstrated in the isolated limb perfusion setting that TNF-{alpha} acts synergistically with cytostatic drugs. The interaction of TNF-{alpha} with TNF receptor 1 and receptor 2 (TNFR-1, TNFR-2) activates several signal transduction pathways, leading to the diverse functions of TNF-{alpha}. The signaling molecules of TNFR-1 have been elucidated quite well, but regulation of the signaling remains unclear. Besides these molecular insights, laboratory experiments in the past decade have shed light upon TNF-{alpha} action during tumor treatment. Besides extravasation of erythrocytes and lymphocytes, leading to hemorrhagic necrosis, TNF-{alpha} targets the tumor-associated vasculature (TAV) by inducing hyperpermeability and destruction of the vascular lining. This results in an immediate effect of selective accumulation of cytostatic drugs inside the tumor and a late effect of destruction of the tumor vasculature. In this review, covering TNF-{alpha} from the molecule to the clinic, we provide an overview of the use of TNF-{alpha} in cancer starting with molecular insights into TNFR-1 signaling and cellular mechanisms of the antitumor activities of TNF-{alpha} and ending with clinical response. In addition, possible factors modulating TNF-{alpha} actions are discussed.




This article has been cited by other articles:


Home page
 J. Immunol.Home page
S. Radfar, Y. Wang, and H. T. Khong
Activated CD4+ T Cells Dramatically Enhance Chemotherapeutic Tumor Responses In Vitro and In Vivo
J. Immunol., November 15, 2009; 183(10): 6800 - 6807.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
Q. Zhang, H. Y. Wang, G. Bhutani, X. Liu, M. Paessler, J. W. Tobias, D. Baldwin, K. Swaminathan, M. C. Milone, and M. A. Wasik
Lack of TNF{alpha} expression protects anaplastic lymphoma kinase-positive T-cell lymphoma (ALK+ TCL) cells from apoptosis
PNAS, September 15, 2009; 106(37): 15843 - 15848.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. A. Warren, S. F. Shoemaker, D. J. Shealy, W. Bshar, and M. M. Ip
Tumor necrosis factor deficiency inhibits mammary tumorigenesis and a tumor necrosis factor neutralizing antibody decreases mammary tumor growth in neu/erbB2 transgenic mice
Mol. Cancer Ther., September 1, 2009; 8(9): 2655 - 2663.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
X. Yuan, X. Lin, G. Manorek, I. Kanatani, L. H. Cheung, M. G. Rosenblum, and S. B. Howell
Recombinant CPE fused to tumor necrosis factor targets human ovarian cancer cells expressing the claudin-3 and claudin-4 receptors
Mol. Cancer Ther., July 1, 2009; 8(7): 1906 - 1915.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. J. Duffy, E. McKiernan, N. O'Donovan, and P. M. McGowan
Role of ADAMs in Cancer Formation and Progression
Clin. Cancer Res., February 15, 2009; 15(4): 1140 - 1144.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. Jiang, R. Goel, M. A. Iftekhar, R. Visaria, J. D. Belcher, G. M. Vercellotti, and J. C. Bischof
Tumor necrosis factor-{alpha}-induced accentuation in cryoinjury: mechanisms in vitro and in vivo
Mol. Cancer Ther., August 1, 2008; 7(8): 2547 - 2555.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. Crippa, A. Gasparri, A. Sacchi, E. Ferrero, F. Curnis, and A. Corti
Synergistic Damage of Tumor Vessels with Ultra Low-Dose Endothelial-Monocyte Activating Polypeptide-II and Neovasculature-Targeted Tumor Necrosis Factor-{alpha}
Cancer Res., February 15, 2008; 68(4): 1154 - 1161.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
P. Hohenberger and W. M. Wysocki
Neoadjuvant Treatment of Locally Advanced Soft Tissue Sarcoma of the Limbs: Which Treatment to Choose?
Oncologist, February 1, 2008; 13(2): 175 - 186.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
R. Goel, D. Swanlund, J. Coad, G. F. Paciotti, and J. C. Bischof
TNF-{alpha}-based accentuation in cryoinjury--dose, delivery, and response
Mol. Cancer Ther., July 1, 2007; 6(7): 2039 - 2047.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Mena, M. Benlloch, A. Ortega, J. Carretero, E. Obrador, M. Asensi, I. Petschen, B. D. Brown, and J. M. Estrela
Bcl-2 and Glutathione Depletion Sensitizes B16 Melanoma to Combination Therapy and Eliminates Metastatic Disease
Clin. Cancer Res., May 1, 2007; 13(9): 2658 - 2666.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. J. Lejeune and A. M.M. Eggermont
Hyperthermic Isolated Limb Perfusion With Tumor Necrosis Factor Is a Useful Therapy for Advanced Melanoma of the Limbs
J. Clin. Oncol., April 10, 2007; 25(11): 1449 - 1450.
[Full Text] [PDF]

Home page
 J. Virol.Home page
J. W. Barrett, J. Sypula, F. Wang, L. R. Alston, Z. Shao, X. Gao, T. S. Irvine, and G. McFadden
M135R Is a Novel Cell Surface Virulence Factor of Myxoma Virus
J. Virol., January 1, 2007; 81(1): 106 - 114.
[Abstract] [Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2006 by AlphaMed Press.
Advertisement